Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Collaboration › Details

Agilent–Florey Institute: mass spectrometry, 201309– collab research protein analysis in neuroresearch using LC-coupled ICP-MS


Period Period 2013-09-19
Organisation Partner, 1st Florey Institute of Neuroscience and Mental Health, Metalloproteomics Laboratory
Products Product proteomics
  Product 2 7700 Series Inductively Coupled Plasma-Mass Spectrometer (ICP-MS) (Agilent)
  Index term 2 Florey Institute–Agilent: mass spectrometer, 201309 supply existent Agilent 7700 ICP-MS coupled to LC at Metalloproteomics Lab at Florey Institute

Agilent Technologies Inc.. (9/19/13). "Press Release: Agilent Technologies Announces Collaboration with Florey Institute of Neuroscience and Mental Health". Melbourne.

Cooperation Will Yield Techniques for Trace-Metal Detection in Proteins Allowing Scientists for the First Time to Probe Metalloproteins Directly from Tissue in Neurodegenerative Diseases

Agilent Technologies Inc. (NYSE: A) today announced a collaboration with the Florey Institute of Neuroscience and Mental Health that will allow scientists to detect and measure metals at the protein level directly from tissue in neurodegenerative diseases such as motor neuron, Parkinson's and Alzheimer's.

For scientists and researchers, the ability to monitor and measure a set of proteins that have metal-binding capacity (metalloproteins) could lead to significant advances in their understanding of disease mechanisms and normal biological processes. Unlocking the role of metalloproteins will provide a more complete picture of what goes wrong during disease processes. This understanding could create new opportunities to develop therapies that target specific metalloprotein dysfunction.

"This is an important breakthrough for the scientific community as we push forward for more effective treatments for a range of neurological and psychiatric conditions," said Dr. Blaine Roberts, senior research scientist at the Florey Institute of Neuroscience and Mental Health.

Scientists recognize that a role for metals in neurodegenerative disease exists but have been able to secure very little molecular detail at the protein level for how changes in the levels of metals such as copper, iron or zinc translate to altered cellular function and disease.

"We are very excited about this collaboration, as it matches the leading-edge brain research of the Florey's and Agilent's leading-edge technologies," said Rod Minett, general manager of Agilent's Life Sciences Group in South Korea and the South Asia-Pacific region. "The emerging field of metalloproteins will help us better understand the human brain and could potentially lead to better clinical outcomes for patients."

The Metalloproteomics Laboratory at the Florey specializes in quantitatively determining the changes of metalloproteins directly from biological material using liquid chromatography techniques coupled with the Agilent 7700 ICP-MS (inductively coupled plasma mass spectrometry). These techniques allow scientists to conduct direct comparison of metalloproteins quickly, produce detailed metalloprotein maps and, most important, reveal the range and complexity of metalloproteins that exist in those biological samples.

"The study of metal-protein interactions and of the biological activity of metalloproteins is critical for understanding how biological systems work," said Dr. Rudolf Grimm, Agilent's director of science and technology and manager of collaborations in the Asia-Pacific region. "This collaboration will help strengthen Agilent's position in the academic research market."

About The Florey Institute of Neuroscience and Mental Health

The Florey is one of the largest brain research institutes in the world and employs 450 neuroscientists across two state-of-the-art research facilities. The Institute also collaborates with researchers in 32 countries and its scientific publications are the third most cited by other scientists. The Florey addresses a variety of conditions and disease states such as Alzheimer's disease, Parkinson's disease, epilepsy, stroke, multiple sclerosis, Huntington's disease, motor neurone disease, traumatic brain and spinal cord injury, depression and addiction.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had net revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at

# # #


Sui-Ching Low
+65 6215 8975

Record changed: 2017-03-17


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Agilent (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81

» top